Biogen was hoping that the efficacy of the drug would be amped up for the 6-mg dose, which had not yet matured in March, with the better tox profile allowing for a safer drug. The spokesman for Biogen noted that the worsening ARIA-E rate among non-ApoE4 carriers was the result of one case.
"When we start breaking down the treatment groups, we are getting into very small sample sizes, and those data reflect one additional patient in the additional 6 months we are reporting," he noted.
Biogen's two Phase III's have already begun, with investigators recruiting 1,350 patients for a 5-year study, according to ClinicalTrials.gov. Analysts, though, expect to see data around 2018 that would help determine where Biogen is headed with this drug.
There are two ongoing ph III trials with Aducanumab. Based on the large number enrolled and the start date of the trials we'd have heard of serious toxicity issues by now.
The Engage and Emerge trials are being done on a global scale. Qualified patients will participate in one or the other, but, not both. Go to this link if you have a family member you'd like to get into the trial. https://www.aducanumabclinicaltrials.com/about-these-studies
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE) Study Start: August 2015 178 locations
https://clinicaltrials.gov/ct2/show/NCT02477800?term=aducanumab&rank=5&submit_fld_opt=
Estimated Enrollment: 1350
Study Start Date: August 2015
Estimated Study Completion Date: February 2022
Estimated Primary Completion Date: February 2020 (Final data collection date for primary outcome measure)
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE) Study Start: September 2015 173 locations
https://clinicaltrials.gov/ct2/show/NCT02484547?term=aducanumab&rank=4&submit_fld_opt=
Estimated Enrollment: 1350
Study Start Date: September 2015
Estimated Study Completion Date: February 2022
Estimated Primary Completion Date: February 2020 (Final data collection date for primary outcome measure)
It's going to be a few years before we get results on efficacy from these ph III's.
Ph I side effects
Amyloid-related imaging abnormalities (ARIAs) were monitored with four MRI scans, read both locally and by a central reader at an imaging CRO. Side effects included headache, diarrhea, and dizziness. They were mild or moderate, some possibly related to the study drug but not to the dose.
Aducanumab | ALZFORUM
http://www.alzforum.org/therapeutics/aducanumab
There is no ph II listed on clinical trials.gov
Only ph I and ph III...
I don't hold long or short here... just watching Alzheimer's trials with hope that one of them come through with some meaningful therapies.
In Reply to 'Cbdpotential'
http://www.fiercebiotech.com/r-d/updated-a-setback-biogen-s-mid-range-dose-of-aducanumab-flops-alzheimer-s-study
To follow KarinCA, click here then click "Follow This Member" under my photo.
Be kinder than necessary, for everyone you meet is fighting some kind of battle.
Recent BIIB News
- Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB • PR Newswire (US) • 06/20/2024 09:45:00 AM
- Shareholders of Biogen Inc. Should Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB • PR Newswire (US) • 06/17/2024 09:45:00 AM
- Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 06/10/2024 09:45:00 AM
- FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease • GlobeNewswire Inc. • 06/09/2024 11:37:43 PM
- FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease • PR Newswire (US) • 06/09/2024 11:30:00 PM
- Investors who lost money on Biogen Inc. (BIIB) should contact The Gross Law Firm about pending Class Action - BIIB • PR Newswire (US) • 06/05/2024 09:45:00 AM
- Economic Worries May Lead To Weakness On Wall Street • IH Market News • 06/04/2024 01:10:54 PM
- Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel • GlobeNewswire Inc. • 06/03/2024 11:30:00 AM
- Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS • GlobeNewswire Inc. • 05/30/2024 08:51:04 PM
- OpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More News • IH Market News • 05/23/2024 11:40:51 AM
- Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis • GlobeNewswire Inc. • 05/16/2024 11:30:14 AM
- Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis • PR Newswire (US) • 05/16/2024 11:30:00 AM
- Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status • GlobeNewswire Inc. • 05/14/2024 11:33:37 PM
- Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status • PR Newswire (US) • 05/14/2024 11:30:00 PM
- Biogen Reports Progress on Corporate Responsibility Priorities • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA • PR Newswire (US) • 03/31/2024 11:30:00 PM
- New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy • GlobeNewswire Inc. • 03/06/2024 12:30:51 PM
- Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting • GlobeNewswire Inc. • 03/04/2024 09:15:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 12:54:07 AM
- Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP • GlobeNewswire Inc. • 02/23/2024 12:00:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/22/2024 03:12:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:39:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:36:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:33:48 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM